GlaxoSmithKline PLC (NYSE:GSK) – Investment analysts at Jefferies Group lowered their FY2018 earnings per share (EPS) estimates for shares of GlaxoSmithKline PLC in a note issued to investors on Tuesday. Jefferies Group analyst J. Holford now expects that the pharmaceutical company will earn $2.80 per share for the year, down from their prior estimate of $2.87. Jefferies Group also issued estimates for GlaxoSmithKline PLC’s FY2019 earnings at $2.93 EPS, FY2020 earnings at $3.22 EPS and FY2021 earnings at $3.48 EPS.

ILLEGAL ACTIVITY NOTICE: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/11/01/glaxosmithkline-plc-to-post-fy2018-earnings-of-2-80-per-share-jefferies-group-forecasts-gsk.html.

GSK has been the subject of several other reports. Citigroup Inc. reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 27th. TheStreet downgraded shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research note on Wednesday, July 26th. Argus reissued a “buy” rating and issued a $50.00 price target on shares of GlaxoSmithKline PLC in a research note on Thursday, August 31st. Zacks Investment Research downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. Finally, Bank of America Corporation downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research note on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $44.33.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 11th. Shareholders of record on Friday, November 10th will be issued a $0.5037 dividend. This represents a $2.01 dividend on an annualized basis and a yield of 5.53%. The ex-dividend date of this dividend is Thursday, November 9th. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. GlaxoSmithKline PLC’s dividend payout ratio is 162.30%.

A number of institutional investors and hedge funds have recently made changes to their positions in GSK. Renaissance Technologies LLC grew its holdings in GlaxoSmithKline PLC by 112.1% in the second quarter. Renaissance Technologies LLC now owns 9,338,000 shares of the pharmaceutical company’s stock worth $402,655,000 after purchasing an additional 4,935,900 shares during the period. FMR LLC grew its holdings in GlaxoSmithKline PLC by 5.9% in the second quarter. FMR LLC now owns 25,024,276 shares of the pharmaceutical company’s stock worth $1,079,047,000 after purchasing an additional 1,389,238 shares during the period. Bank of America Corp DE grew its holdings in GlaxoSmithKline PLC by 15.8% in the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock worth $288,780,000 after purchasing an additional 934,928 shares during the period. Federated Investors Inc. PA grew its holdings in GlaxoSmithKline PLC by 22.7% in the second quarter. Federated Investors Inc. PA now owns 4,511,155 shares of the pharmaceutical company’s stock worth $194,521,000 after purchasing an additional 833,501 shares during the period. Finally, Marshall Wace North America L.P. grew its holdings in GlaxoSmithKline PLC by 148.0% in the second quarter. Marshall Wace North America L.P. now owns 1,119,491 shares of the pharmaceutical company’s stock worth $48,138,000 after purchasing an additional 668,088 shares during the period. Institutional investors and hedge funds own 9.29% of the company’s stock.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Earnings History and Estimates for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.